BRGX (BioRegenx) Beta: -0.8924 (As of Jul. 09, 2026)


What is BioRegenx Beta?

BioRegenx BRGX Beta is -0.8924 as of Jul. 09, 2026. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-09), BioRegenx's Beta is -0.8924.

BioRegenx  (OTCPK:BRGX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

BioRegenx Beta Related Terms

BioRegenx Beta Historical Data

* Premium members only.

The historical data trend for BioRegenx's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRegenx Beta Chart

BioRegenx Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.50 -3.44 -3.36 -2.74 -0.29

BioRegenx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.47 -4.76 -6.66 -0.29 -0.50

BRGX vs VYND, ACON, WLSS: Beta Comparison

For the Health Information Services subindustry, BioRegenx's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRegenx Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioRegenx's Beta distribution charts can be found below:

* The bar in red indicates where BioRegenx's Beta falls into.


BioRegenx Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.8924 mean?
BioRegenx (BRGX) has a Beta of -0.8924 as of Jul. 09, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioRegenx and its competitors.
Is BioRegenx's Beta too high?
BioRegenx's current Beta is -0.8924.
How does BioRegenx's Beta compare to VYND and ACON?
BioRegenx's Beta of -0.8924 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioRegenx and its competitors. BioRegenx's current Beta is -0.8924. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRegenx stock overvalued right now?
Based on GuruFocus' analysis, BioRegenx (BRGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 24% below its estimated fair value. The current Beta is -0.8924. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BioRegenx (BRGX), the current Beta is -0.8924 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioRegenx Business Description

Address 7407 Ziegler Road, Chattanooga, TN, USA, 37421
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. It focuses on commercialization of its patented technologies in its field.